Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy

Tomoka Nishimura; Kiichiro Ninomiya; Mitsutaka Nakashima; Satoshi Akagi; Tadahiro Kuribayashi; Hisao Higo; Katsuyuki Hotta; Yoshinobu Maeda; Hiroshi Itoh; Katsuyuki Kiura

doi:10.2169/internalmedicine.0505-22

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy

Tomoka Nishimura, Kiichiro Ninomiya, Mitsutaka Nakashima, Satoshi Akagi, Tadahiro Kuribayashi, Hisao Higo, Katsuyuki Hotta, Yoshinobu Maeda, Hiroshi Itoh, Katsuyuki Kiura

Research output: Contribution to journal › Article › peer-review

4 Citations (Scopus)

Abstract

A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.

Original language	English
Pages (from-to)	1319-1322
Number of pages	4
Journal	Internal Medicine
Volume	62
Issue number	9
DOIs	https://doi.org/10.2169/internalmedicine.0505-22
Publication status	Published - 2023

Keywords

case report
irAE
myocarditis
nivolumab plus ipilimumab

ASJC Scopus subject areas

Internal Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2169/internalmedicine.0505-22

Cite this

@article{14053f211c3c464f82ff9c95b0afe22f,

title = "Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy",

abstract = "A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.",

keywords = "case report, irAE, myocarditis, nivolumab plus ipilimumab",

author = "Tomoka Nishimura and Kiichiro Ninomiya and Mitsutaka Nakashima and Satoshi Akagi and Tadahiro Kuribayashi and Hisao Higo and Katsuyuki Hotta and Yoshinobu Maeda and Hiroshi Itoh and Katsuyuki Kiura",

year = "2023",

doi = "10.2169/internalmedicine.0505-22",

language = "English",

volume = "62",

pages = "1319--1322",

journal = "Internal Medicine",

issn = "0918-2918",

publisher = "Japanese Society of Internal Medicine",

number = "9",

}

TY - JOUR

T1 - Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy

AU - Nishimura, Tomoka

AU - Ninomiya, Kiichiro

AU - Nakashima, Mitsutaka

AU - Akagi, Satoshi

AU - Kuribayashi, Tadahiro

AU - Higo, Hisao

AU - Hotta, Katsuyuki

AU - Maeda, Yoshinobu

AU - Itoh, Hiroshi

AU - Kiura, Katsuyuki

PY - 2023

Y1 - 2023

N2 - A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.

AB - A 59-year-old man with a high level of antinuclear antibody received nivolumab and ipilimumab plus chemotherapy for lung cancer. Two weeks after the second course, he was admitted with a fever and severe fatigue. Laboratory studies showed elevated markers of myocardial damage, and a myocardial biopsy showed inflammatory cell infiltration, damaged myocardial fibers. Myocarditis was diagnosed as an immune-related adverse event (irAE), and high-dose corticosteroids were initiated. However, his cardiac function rapidly worsened, and he died on the fifth day after admission. There is no established treatment strategy for fulminant myocarditis as an irAE, and the further exploration of viable treatment strategies is required.

KW - case report

KW - irAE

KW - myocarditis

KW - nivolumab plus ipilimumab

UR - http://www.scopus.com/inward/record.url?scp=85152582571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85152582571&partnerID=8YFLogxK

U2 - 10.2169/internalmedicine.0505-22

DO - 10.2169/internalmedicine.0505-22

M3 - Article

C2 - 36130891

AN - SCOPUS:85152582571

SN - 0918-2918

VL - 62

SP - 1319

EP - 1322

JO - Internal Medicine

JF - Internal Medicine

IS - 9

ER -

Fulminant Myocarditis for Non-small-cell Carcinoma of the Lung with Nivolumab and Ipilimumab Plus Chemotherapy

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this